

Claims

1. Peptide comprising the sequence of amino acids selected from:
 - the sequence 13-39 of the HARP factor ; and
 - 5 - the sequence 65-97 of the HARP factor.
2. Peptide comprising a sequence of amino acids at least 80 % similar to the sequence SEQ ID N° 2 or N° 3, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to glycoaminoglycans (GAG).
- 10 3. Peptide according to Claim 2, in which the sequence differs from the sequence SEQ ID N° 2 or N° 3 by the conservative substitution of at least one amino acid.
4. Nucleic acid comprising a sequence coding for a peptide as defined in any one of Claims 1 to 3.
5. Nucleic acid according to Claim 4, comprising the sequence SEQ ID N° 5 or
15 SEQ ID N° 6.
6. Method of production of a peptide as defined in any one of Claims 1 to 3, comprising the synthesis of the said peptide by chemical means.
7. Method of production of a peptide as defined in any one of Claims 1 to 3, in which a vector containing a nucleic acid as defined in Claim 4 or 5 is transferred into a
20 host cell which is cultured under conditions permitting the expression of the corresponding peptide.
8. Pharmaceutical composition comprising a peptide as defined in any one of Claims 1 to 3, and one or more pharmaceutically acceptable excipients.
9. Composition according to Claim 8, further comprising a peptide having the
25 sequence of amino acids 111-136 of the HARP factor or a peptide comprising a sequence of amino acids at least 80 % similar to the sequence SEQ ID N° 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

10. Composition according to Claim 9, comprising :
 - the peptide 13-39 of sequence SEQ ID N° 2 ;
 - the peptide 65-97 of sequence SEQ ID N° 3 ; et
 - the peptide 111-136 of sequence SEQ ID N° 4.
- 5 11. Pharmaceutical composition comprising a nucleic acid comprising a sequence coding for a peptide as defined in any one of Claims 1 to 3.
12. Composition according to Claim 11, further comprising a nucleic acid comprising a sequence coding for a peptide as defined in Claim 9.
13. Composition according to Claim 12, comprising :
 - 10 - a nucleic acid coding for the peptide 13-39 of sequence SEQ ID N° 2 ;
 - a nucleic acid coding for the peptide 65-97 of sequence SEQ ID N° 3 ;
 - a nucleic acid coding for the peptide 111-136 of sequence SEQ ID N° 4.
14. Composition according to Claim 12 or 13, in which the said nucleic acids are carried by one single vector.
- 15 15. Use of a peptide as defined in any one of Claims 1 to 3 for the preparation of a medicament intended for the treatment of a pathology associated with an angiogenesis.
16. Use according to Claim 15, in which the peptide as defined in any one of Claims 1 to 3 is associated with a peptide having the sequence of amino acids 111-136 of the HARP factor or with a peptide comprising a sequence of amino acids at least 80
 - 20 % similar to the sequence SEQ ID N° 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.
17. Use of a nucleic acid as defined in either Claim 4 or Claim 5 for the preparation of a medicament intended for the treatment of a pathology associated with an angiogenesis.

18. Use according to Claim 17, in which the nucleic acid as defined in either Claim 4 or Claim 5 is associated with a nucleic acid comprising a sequence coding for a peptide as defined in Claim 9.
19. Use according to any one of Claims 15 to 18, in which the pathology is a
5 tumour, an ocular lesion, rheumatoid polyarthritis or a skin disease.